伊贝沙坦与苯那普利、卡托普利对高血压肾病患者尿总蛋白排泄量及内生肌酐清除率影响的比较

目的 :观察伊贝沙坦 (irbesartan)和血管紧张素转换酶抑制剂对高血压肾病患者尿总蛋白排泄量 (UPER)与内生肌酐清除率 (Ccr)的影响 ,比较不同的血管紧张素拮抗剂上述作用的差别。方法 :以序贯试验的方法选择了用伊贝沙坦或苯那普利中卡托普利治疗的高血压肾病患者共 6 6例 ,分为人数相等的 3组 ,进行了治疗前、后 3组间降压效果、UPER、Ccr的比较。结果 :伊贝沙坦了压效果与苯那普利、卡托普利相似 ,但伊贝沙坦对UPER、Ccr的效果优于苯那普利和卡托普利 ,3组比较有统计学的差异 (P <0 .0 1)。伊贝沙坦组未见于干咳现象 ,而苯那普利组及卡托普利组分别干咳发生率分别为 4 .5 %和 13.6 %。结论 :肾功能轻、中度损害的高血压肾病患者服用伊贝沙坦 ,不仅可有效降低血压 ,还可以更好地降低UPER ,提高Ccr。

COMPARISON BETWEEN EFFECTS OF IRBESARTAN,BENAZEPRIAL AND CAPTOPRIL ON THE EXCRETION RATE OF URINARY PROTEIN AND THE CLEARANCE OF ENDOGENOUS CREATININE IN HYPERTENSION-RELATED NEPHROPATHY

Objective: To evaluate the effects of irbesartan, benazeprial and captopril on the Excretion Rate of Urinary Protein (UPER) and the Clearance of Endogenous Creatinine (Ccr) in patients with hypertension- related nephropathy. Methods:In this consecutive study, 66 cases of hypertension-related nephropathy were included. The patients were divided into 3 groups according to the anti-hypertension drugs, including irbesartan, benazeprial and captopril, they used. Comparison was major in the anti-hypertensive effect, UPER and Ccr that were determined before and after the treatment.Results:The anti-hypertensive effect rate in irbesartan, benazeprial and captopril group were 96%, 93% and 94% respectively. Decrease of UPER was occurred in 91% of cases in irbesartan group, and 61%, 55% in benazeprial group and captopril group respectively. Conclusion:Ccr were improved in 93%, 82% and 60% of patients in irbesartan group, benazeprial group and captopril group respectively.